This study is for children and young adults with certain cancers called INI1-negative tumors. The study is looking at two drugs, nivolumab and ipilimumab, that help the immune system fight cancer. These drugs are called immunotherapy drugs. This is a Phase II trial, which means it checks if the drugs are safe and if they work for this type of cancer. The U.S. Food and Drug Administration (FDA) has approved these drugs for other diseases, but not for the specific cancers in this study.

Here are some key points to consider:

• Duration & Visits: The study might involve frequent hospital visits for tests and treatments.
• Eligibility: Participants must have specific types of tumors and meet health requirements.
• Risks and Safety: The drugs are being tested, so there are unknown risks, and participants will be monitored closely.

If you decide to join, you will need to meet certain health standards, and you cannot participate if you're pregnant or have certain other health issues. Participants will need to follow specific guidelines, including using birth control during and after the study.